Genaissance launches gene test for heart defects:
This article was originally published in Clinica
Executive Summary
Genaissance Pharmaceuticals has launched a pharmacogenomic test for cardiac channelopathies - a broad clinical category that includes Long QT and Brugada Syndromes, two causes of arrhythmia that can result in sudden cardiac death. The CLIA-compliant test can confirm the presence of mutations known to cause cardiac channelopathies; identify family members who have similar mutations; and assist physicians in choosing the most appropriate course of treatment for each patient. It works by detecting genetic mutations in five cardiac ion channel genes. It is expected to provide an improvement to cardiac channelopathies testing using traditional electrocardiograms, which may miss a diagnosis, leaving a patient at risk of a sudden cardiac death, said the New Haven, Connecticut firm.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.